Comunicados de prensa Novartis Salud y ciencias de la vida — Feed RSS y monitoreo en vivo
PPN World indexa los comunicados de prensa de Novartis y archiva cada publicación. Esta fuente está en silencio desde el 21 de julio de 2026 — sus 21 comunicados indexados siguen disponibles, y una alerta te avisará en cuanto vuelva a publicar.
URL del feed RSS de Novartis
https://hpampthnhbmgpdxezfop.supabase.co/functions/v1/scrape-config?config=novartis-com-media-releasesSobre este feed
Novartis forma parte de los más de 1200 feeds de comunicados que PPN World monitorea de forma continua — una fuente en inglés centrada en el sector Salud y ciencias de la vida, clasificada bajo «Suiza» en nuestro índice por país. Cada comunicado se deduplica, se geolocaliza y se enriquece con un resumen de IA, y puedes añadir alertas de búsquedas guardadas sobre cualquier palabra clave que publique. El comunicado más reciente de nuestro índice se publicó el 21 de julio de 2026; la fuente está en silencio desde entonces.
Cómo seguir los comunicados de Novartis
- Copia la URL del feed RSS de Novartis que aparece arriba.
- Pégala en cualquier lector RSS (Feedly, Inoreader, NetNewsWire…) para recibir el feed sin procesar.
- O sigue Novartis en PPN World para añadir deduplicación, alertas de búsquedas guardadas y resúmenes con IA en los más de 1200 feeds.
Comunicados de Novartis — archivo
- Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmedhace 9 d
Ad hoc announcement pursuant to Art. 53 LRSecond quarterNet sales grew +1% (cc1, +3% USD), with core operating income1 flat (cc and USD)Sales growth driven by priority brands including Kisqali (+43%…
- Novartis verzeichnete im zweiten Quartal Umsatzsteigerungen und baute die Pipeline weiter aus; Prognose für das Geschäftsjahr bekräftigthace 9 d
Ad-hoc-Mitteilung gemäss Art. 53 KRZweites QuartalDer Nettoumsatz stieg um +1% (kWk1, +3% USD), das operative Kernergebnis1 blieb unverändert (kWk und USD)Das Umsatzwachstum beruhte auf den…
- Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgANhace 13 d
Fabhalta slowed eGFR decline by 48% vs placebo over two years, demonstrating kidney function preservation1 Clinically meaningful improvements of protein in urine observed as early as two weeks,…
- Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patientshace 24 d
Adds potential first-in-class, N-myristoyltransferase inhibitor (NMTi) antibody-drug conjugate (ADC) payload platform, designed to address resistance to current payloads Strengthens the Novartis…
- Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)hace 28 d
First gene replacement therapy in the EU for broad population with SMA, including children two years and older, teens and adults Fixed, one-time dose designed to replace the faulty SMN1 gene,…
- Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)hace 48 d
Rhapsido demonstrated statistically significant and clinically meaningful symptom control in twice as many patients vs placebo1, with favorable safety profile and no observed liver safety…
- Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpointhace 49 d
Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consistent with previous…
- Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026hace 52 d
Results from Rhapsido (remibrutinib) pivotal Phase III RemIND trial, the largest study in chronic inducible urticaria, to be highlighted in late-breaker oral presentationNew Phase IIIb REMIXED…
- Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 yearshace 56 d
Phase III ALIGN study results showed reduced rate of kidney function decline by ~34% with Vanrafia vs placebo, based on supportive eGFR slope analysis1Vanrafia reduced protein in urine by 38.3% vs…
- Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patientshace 57 d
Clinically meaningful, statistically significant efficacy achieved in primary and all secondary endpoints, including reduced steroid use; safety consistent with established Cosentyx profile1,…
- Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CMLhace 59 d
Growing improvement in major molecular response (MMR) rates demonstrated with Scemblix vs. all standard-of-care TKIs including imatinib and second generation (2G) TKIs1 Clinically relevant 15.2%…
- Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseaseshace 59 d
New Cosentyx® (secukinumab) data from REPLENISH, largest ever global Phase III trial in polymyalgia rheumatica, to be highlighted in oral sessionNew ianalumab interim results from Sjögren’s Phase III…
Los comunicados más recientes de esta fuente se transmiten en vivo para los miembros de PPN World.
Preguntas frecuentes
¿Cómo seguir los comunicados de Novartis en tiempo real?+
¿Existe un feed RSS de Novartis?+
¿Cuál es la URL del feed RSS de Novartis?+
¿Qué tipo de comunicados publica Novartis?+
Feeds relacionados
- Presseportal (Schweiz)
- Presseportal Schweiz (PPS)
- Swiss-Press.com (HELP Media)
- République et canton de Genève — Communiqués et publications
- Stadt Zürich — Medienmitteilungen
- Kanton Bern Medienmitteilungen
- Swiss National Bank
- EPFL News
- Kanton Graubünden — Medienmitteilungen Standeskanzlei
- Ville de Genève — Actualités